Background illustration for clinical trials search

Ovarian Cancer Clinical Trials

Browse 1,660 ovarian cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1
Active & Responsive

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

for
Cancer, Breast Cancer, Lung Cancer, Colon Cancer,
Location: Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18+

Code: NCT03702309

Recruiting
Active & Responsive

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

for
Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver,
Location: Scarborough ME, Worcester MA, Hartford CT, Norwalk CT,
Sponsor: Massive Bio, Inc.

Sex: All

Age: 0+

Code: NCT03452774

Recruiting
Active & Responsive

A Study of PHST001 in Advanced Solid Tumors

for
Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer,
Location: Boston MA, New Haven CT, Lake Success NY, New York NY,
Sponsor: Pheast Therapeutics

Sex: All

Age: 18+

Code: NCT06840886

Phase 1, Recruiting
Active & Responsive

A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer

for
Anatomic Stage I Breast Cancer AJCC v8,
Location: Upland CA, Irvine CA, Lancaster CA, Duarte CA,
Sponsor: City of Hope Medical Center

Sex: Female

Age: 18+

Code: NCT07741968

Recruiting
Active & Responsive

The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer

for
Advanced Solid Tumor Cancer,
Location: Aurora CO, Boulder CO
Sponsor: University of Colorado, Boulder

Sex: All

Age: 18+

Code: NCT07636200

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

for
Breast Cancer, Endometrial Cancer, Ovarian Cancer,
Location: Boston MA, Fairfax VA, Orlando FL, Cleveland OH,
Sponsor: Terremoto Biosciences Inc.

Sex: All

Age: 18+

Code: NCT07109726

Phase 1, Phase 2, Recruiting
Active & Responsive

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

for
Platinum-resistant Ovarian Cancer,
Location: Stony Brook NY, Greenville NC, Silver Spring MD,
Sponsor: Genelux Corporation

Sex: Female

Age: 18+

Code: NCT05281471

Phase 3, Recruiting
Active & ResponsiveNew

Phase 1 Study of VT-101 in Advanced Ovarian Cancer

for
Epithelial Ovarian Cancer, Ovarian Cancer
Location: Iowa City IA
Sponsor: Michael J. Goodheart

Sex: Female

Age: 18 - 70+

Code: NCT07905677

Phase 1, Recruiting
Active & Responsive

UNTOLD Ovarian Cancer Unmet Needs Survey

for
Ovarian Cancer
Location: Minneapolis MN
Sponsor: Masonic Cancer Center, University of Minnesota

Sex: Female

Age: 18+

Code: NCT07070726

Recruiting
Active & Responsive

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

for
Ovarian Cancer, Fallopian Tube Cancer
Location: Boston MA, New York NY, Philadelphia PA, Durham NC,
Sponsor: M.D. Anderson Cancer Center

Sex: Female

Age: 18+

Code: NCT05287451

Recruiting
Active & Responsive

Healthy Volunteers Study

for
Ovarian Cancer, Genetic Predisposition to Disease
Location: Philadelphia PA
Sponsor: Abramson Cancer Center at Penn Medicine

Sex: Female

Age: 30 - 50

Code: NCT06962059

Recruiting
Active & ResponsiveNew

Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer

for
Ovarian Cancer, BRCA Mutation
Location: Philadelphia PA
Sponsor: Abramson Cancer Center at Penn Medicine

Sex: Female

Age: 25+

Code: NCT06436248

Recruiting
Active & Responsive

Prehabilitation in High-risk Oncologic Surgery

for
Pancreatic Cancer, Colo-rectal Cancer, Gastric Cancer,
Location: Philadelphia PA
Sponsor: Fox Chase Cancer Center

Sex: All

Age: 18+

Code: NCT07638410

Recruiting
Active & Responsive

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

for
Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic,
Location: Hackensack NJ, Fairfax VA, Buffalo NY, Cleveland OH,
Sponsor: Whitehawk Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07444814

Phase 1, Recruiting
Active & Responsive

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

for
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer,
Location: Dothan AL, Grand Rapids MI, Omaha NE, Houston TX
Sponsor: Radiopharm Theranostics, Ltd

Sex: All

Age: 18+

Code: NCT07189871

Phase 1, Phase 2, Recruiting
Active & Responsive

Cognitive Impact of Neoadjuvant Chemotherapy for Gynecologic Cancers

for
Ovarian Cancer, Cognitive Change
Location: Madison WI
Sponsor: University of Wisconsin, Madison

Sex: Female

Age: 18+

Code: NCT07125209

Recruiting
Active & Responsive

IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

for
Fallopian Tube Carcinoma, Ovarian Carcinoma,
Location: Seattle WA
Sponsor: University of Washington

Sex: Female

Age: 18+

Code: NCT07495124

Phase 2, Recruiting
Active & Responsive

Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT

for
Ovarian Cancer, Cognitive Impairment
Location: Orange CA
Sponsor: University of California, Irvine

Sex: Female

Age: 18+

Code: NCT04520139

Phase 1, Phase 2, Recruiting
Active & Responsive

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

for
Triple Negative Breast Cancer, HER2-negative Breast Cancer,
Location: Fairfax VA, Orlando FL, Huntersville NC, Sarasota FL,
Sponsor: Dren Bio

Sex: All

Age: 18+

Code: NCT06999187

Phase 1, Recruiting
Active & Responsive

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

for
Advanced Solid Tumors, Genital Neoplasm, Female,
Location: Boston MA, Bethesda MD, Toronto, Celebration FL,
Sponsor: Marengo Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05592626

Phase 1, Phase 2, Recruiting

What is ovarian cancer?

Ovarian cancer begins in or near the ovaries. About 9 in 10 cases are epithelial, and most of those are high grade serous tumors that research now shows usually start in the fallopian tubes rather than the ovary. Rarer types begin in the egg cells or in hormone producing cells. It is hard to catch early. The ovaries sit deep in the pelvis, and early symptoms like bloating, pelvic or back pain, feeling full quickly, and urinary urgency are vague and common. The most frequent sign at diagnosis is abdominal swelling from fluid, which means the cancer is already advanced.

Treatment has changed. Surgery to remove as much tumor as possible, followed by platinum chemotherapy, is still the foundation. Since 2014 PARP inhibitor pills have been used to delay recurrence in BRCA mutated and similar tumors, and testing every patient for these mutations is now standard. In 2022 the first antibody drug conjugate for ovarian cancer was approved for platinum resistant disease, with full approval in 2024. Prevention has moved too. Because most cancers start in the tubes, removing only the fallopian tubes during other pelvic surgery is being tested as a way to prevent cancer without early menopause.

Ovarian cancer shares its inherited risk genes with breast, pancreatic, and prostate cancer. Our cancer treatment guide explains how targeted therapies work.

Types of ovarian cancer clinical trials

How is ovarian cancer diagnosed and tested?

Who can participate in ovarian cancer clinical trials?

The stages of ovarian cancer, and why they matter for trials

How to enroll in an ovarian cancer clinical trial